5 hours ago
Manne-Goehler discusses a recent study highlighting the scope and scale at which GLP-1 receptor agonists can reduce obesity and its associated risks.
9 hours ago
Investigators ranked the short-term effectiveness of 4 oral JAKis, upadacitinib, abrocitinib, baricitinib, and ivarmacitinib in moderate-to-severe atopic dermatitis.
11 hours ago
CMTX-101 met safety endpoints in a phase 1b/2a cystic fibrosis study, with meaningful reductions in inflammatory biomarkers and pulmonary Pseudomonas aeruginosa burden.
13 hours ago
The FDA has extended its review of the sNDA, delaying the previous January 13, 2026, PDUFA date, to April 13, 2026.
13 hours ago
An FDA review found no increased risk of SI/B associated with the use of GLP-1 RA medications, including liraglutide, semaglutide, and tirzepatide.